Pfizer has increased its full-year financial guidance, driven by positive momentum from recently launched and acquired products. This adjustment comes as the pharmaceutical giant works to offset declining revenue from its Covid-19 vaccine and treatment lines. The update reflects confidence in the company's diversified pipeline as it navigates post-pandemic market dynamics.
Source: Wall Street Journal US Business · Summarized by HeadlinesBriefing